XVARY Composite Score
24
/ 100
Weak
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Vaccinex is a tiny biotech trying to turn one antibody program into treatments for cancer and brain disease.
How it gets paid
Last year Vaccinex made $601K in revenue. Collaboration, grants & other was the main engine at $601K, or 100% of sales.
What just happened
FY2024 anchor: ~$601K revenue and deep losses in summarized third-party pulls of filings).
At a Glance
N/a balance sheet
50/100 earnings predictability — expect surprises
-$8.88 fy2024 eps est
$1M fy2024 rev est
Deep losses vs. tiny revenue — operating margin is not the right frame
XVARY composite: 24/100 — weak
What They Do
Vaccinex is a tiny biotech trying to turn one antibody program into treatments for cancer and brain disease.
The whole story is pepinemab. One platform, multiple Phase II shots on goal. If you own this, you are betting that a 23-person team can stretch one antibody across Alzheimer’s, Huntington’s, and cancer before the cash runs out.
How They Make Money
$601K
FY2024 total revenue (SEC income statement — update when 2025 10-K posts)
Collaboration, grants & other (consolidated)
$601K
FY2024 filed
The Products That Matter
Clinical-stage therapeutic candidate
pepinemab
1 lead asset · 100% of the story
pepinemab is the only clinical asset named on this page, and that matters because the company has just $601K in annual revenue to fall back on if trial results disappoint.
binary setup
Current operating revenue
collaboration and other revenue
$601K annual revenue
this is the entire reported revenue base today. At $601K, it tells you the company is still funded by capital markets and milestones, not by a self-sustaining business.
tiny base
Key Numbers
-$8.88
FY2024 diluted EPS (filed)
$1M
FY2024 revenue (filed)
n/a
trailing p/e
n/a
dividend yield
Financial Health
n/a
Strength
- balance sheet grade n/a
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
P0: Vaccinex SEC filings (CIK 0001205922) — https://www.sec.gov/edgar/browse/?CIK=0001205922
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
verify on SEC
FY2024 anchor: ~$601K revenue and deep losses (diluted EPS about -$(8.88) in summarized third-party pulls of filings).
We are not pasting another quarter’s revenue/EPS here without a fresh exhibit. Open the latest 10-Q for the current period — micro-cap biotech numbers change fast and bad scrapes scale horribly.
$601K
FY2024 revenue
-$(8.88)
FY2024 EPS (check 10-K)
SEC
source of truth
the discipline
If revenue is under $1M, every “% vs. prior year” line is entertainment unless the filing period matches.
P0: SEC company filings — https://www.sec.gov/edgar/browse/?CIK=0001205922 · IR: https://ir.vaccinex.com/financial-information/sec-filings/
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk here is pepinemab failing to create real clinical value before the company needs more cash. That is a Vaccinex-specific problem, not a generic biotech disclaimer.
Med
Single-asset dependency
Pepinemab is the only named clinical asset on this page. If it disappoints, the company falls back on just $601K in annual revenue and no visible diversification.
That means one data set effectively carries 100% of the equity story.
Med
Financing and dilution
Vaccinex had $1.11M in total cash while the business was still expected to lose $8.88 per share. That is not a comfortable cash cushion for a clinical-stage company.
If capital needs arrive before meaningful data, existing shareholders can get diluted from a weak negotiating position.
Med
Liquidity shock
At roughly $2M in market cap, VCNX is tiny even by micro-cap standards. The December 2025 removal from the S&P TMI Index did not help.
Thin trading can turn small updates into large price swings. You may be right on the science and still hate the tape.
Med
Commercialization gap
The current business generated only $601K in annual revenue. That means there is no operating engine here to offset delays, setbacks, or extra trial expense.
Until revenue becomes more than a rounding error, every setback hits valuation directly.
A forced financing or weak pepinemab data would hit a company that already has just $601K in revenue and $1.11M in cash. That is what binary risk looks like in numbers.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Calendar
May 18, 2026 earnings update
This is the next scheduled public checkpoint. At VCNX's size, even a routine filing can change the financing picture fast.
Metric
Cash versus burn
The company disclosed $1.11M in cash while estimated FY2024 EPS sits at -$8.88. Watch whether cash lasts long enough to reach meaningful data.
Clinical
Pepinemab trial language
You are looking for evidence that management can talk about pepinemab with more than hope. Any concrete efficacy or trial-progress detail matters here.
Market structure
Post-index-removal trading conditions
The December 2025 S&P TMI Index removal can reduce visibility and liquidity. Watch volume and price gaps, not just headlines.
Analyst Rankings
earnings predictability
50 / 100
Middle of the pack on predictability. In human-speak, analysts do not have a stable business model here to model with confidence.
risk rank
5
Safer than just 5% of stocks in the data set. That is an unusually weak reading and it fits the one-asset, low-cash setup.
Source: institutional data
Institutional Activity
institutional ownership data for VCNX is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$1
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive